Dexcom Inc
(NQ:
DXCM
)
69.96
+1.05 (+1.52%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dexcom Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
31
32
Next >
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
April 10, 2024
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments
Via
InvestorPlace
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
April 10, 2024
Via
Benzinga
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating
April 08, 2024
The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.
Via
Investor's Business Daily
2 Growth Stocks to Buy Hand Over Fist in April
April 08, 2024
These healthcare companies' target markets substantially overlap.
Via
The Motley Fool
7 Nasdaq Stocks to Sell in April Before They Crash & Burn
April 03, 2024
The momentum in growth companies is likely to run out. Move on from these Nasdaq stocks to sell in April before it's too late.
Via
InvestorPlace
Dexcom Publishes Annual Sustainability Report
April 03, 2024
From
DexCom, Inc.
Via
Business Wire
DexCom Inc Chart Analysis
March 26, 2024
Technical analysis of the stock chart for DXCM.
Via
Talk Markets
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
March 25, 2024
Via
Benzinga
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
April 02, 2024
From
DexCom, Inc.
Via
Business Wire
DexCom Stock Gains from GLP-1 Diabetic Users
April 02, 2024
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
Via
MarketBeat
3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List
April 01, 2024
The S&P 500’s current P/E ratio is 30% higher than a year ago, making it easier to find overvalued S&P 500 stocks to buy.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Micron, Dropbox And 2 Other Stocks Insiders Are Selling
April 01, 2024
The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
NASDAQ:DXCM—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
March 21, 2024
DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating.
Via
Chartmill
DexCom's Options: A Look at What the Big Money is Thinking
March 20, 2024
Via
Benzinga
Market Cap Game Show: Andy Cross vs. Bill Mann
March 30, 2024
Join the "Rule Breaker Investing" fun.
Via
The Motley Fool
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
March 26, 2024
Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year.
Via
Investor's Business Daily
Two Hot AI Stocks Lead S&P 500 Monday
March 25, 2024
Super Micro and Micron , two big winners in 2024, led the way Monday.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’
March 25, 2024
Investors should take notice of these stocks with high analyst ratings. It's time to load up your portfolio.
Via
InvestorPlace
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
March 23, 2024
DexCom, Blackstone and Royal Caribbean head this list of five stocks.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
March 14, 2024
Via
Benzinga
Analyst Expectations For DexCom's Future
March 12, 2024
Via
Benzinga
Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
March 19, 2024
The Relative Strength (RS) Rating for Edwards Lifesciences stock jumped into a new percentile Tuesday, with a rise from 78 to 81.
Via
Investor's Business Daily
DexCom Stock Trying To Close In On Key Technical Benchmark
March 18, 2024
In a welcome move, medical device DexCom stock saw its Relative Strength Rating improve from 68 to 73 on Monday.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
March 18, 2024
Via
Benzinga
DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says
March 12, 2024
DexCom Inc’s (NASDAQ: DXCM) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-counter (OTC)
Via
Benzinga
Tandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher
March 11, 2024
On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78.
Via
Investor's Business Daily
ServiceNow Setting Up As Three Stocks Flash Buy Signals
March 09, 2024
All four stocks to watch boast solid earnings growth.
Via
Investor's Business Daily
2 Medical Device Stocks to Buy Hand Over Fist in March
March 08, 2024
Don't let their modest gains over the past year mislead you; these stocks can make for great long-term investments.
Via
The Motley Fool
Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades'
March 07, 2024
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named SL Green Realty Corp.
Via
Benzinga
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
March 06, 2024
FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.